What's New
The Lived Experience of FTD: Managing the Emotional Impact of Job Loss in FTD
When someone is diagnosed with FTD, it is almost guaranteed that they will eventually have to leave their job, usually long before they are ready to do so. The abrupt…
Remember Me Podcast Discusses Grief with AFTD Staff in Recent Episode
In a special bonus episode of the “Remember Me” podcast, AFTD Support & Education Director Esther Kane, MSN, RN-CDP, and Support Services Manager Sarah Lopata, MS joined hosts Rachael Martinez…
AFTD Webinar: Paving the Path Forward — Advancing AFTD’s Public Policy Priorities
Families living with FTD have significant unmet needs: access to quality dementia care, policies that are friendlier to unpaid caregivers, and a deeper public investment into disease-modifying treatments. In this…
Upcoming UCSF Trial to Evaluate Effectiveness of Three Drugs for PSP
An upcoming clinical trial conducted by the University of California, San Francisco (UCSF) will simultaneously evaluate multiple drugs to determine their effectiveness against progressive supranuclear palsy. The trial has been…
February 22, 2025: In-Person Meet & Greet in Sparks, Nev.
AFTD Ambassador Scott Oxarart invites anyone impacted by FTD to join others on the FTD journey for a two-mile walk beginning at Nevada Veterans Memorial Plaza in Sparks (300 Howard…
February 9, 2025: Seattle, Wash. Virtual Meet & Greet
Join and learn from others who understand the FTD journey at this virtual AFTD Meet & Greet event for people in Seattle, Wash., and its surrounding communities on Sunday, February…
Making a Difference: AFTD Introduces First-Ever Advocacy Agenda
AFTD has unveiled a robust and ambitious advocacy agenda for 2025, emphasizing the urgent need to better support families facing FTD while pushing for deeper public investments into FTD research…
In TEDx Talk, Neuroscientist Shares Her Father’s FTD Story and Her Hope for Dementia Research Breakthroughs
Leila Allen, PhD, of Florida International University (FIU), discussed the groundbreaking dementia research that she and her colleagues are performing with pig models and artificial intelligence during a recently published…
Extracellular Vesicles in Plasma Could be FTD-ALS Diagnostic Biomarker, Study Finds
A study published in Nature Medicine finds that a type of particle associated with specific cell subtypes could potentially be utilized as a biomarker for FTD and ALS disorders. The…
Denali and Takeda Open FTD-GRN Clinical Trial Site at UPenn
Denali Therapeutics and Takeda Pharmaceutical Company’s phase 1/2 clinical trial for FTD caused by GRN mutations is opening its first U.S.-based trial site at the University of Pennsylvania (UPenn). The…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)